Supplementation with a 9c,11t-rich conjugated linoleic acid blend shows no clear inhibitory effects on platelet function in healthy subjects at low and moderate cardiovascular risk: A randomized controlled trial

Eva-Maria Bachmair, Sharon G Wood, Hiskias G Keizer, Graham W Horgan, Isobel Ford, Baukje de Roos

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Scope
The 9cis,11trans-conjugated linoleic acid (9c,11t-CLA) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated human platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t-CLA enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial.

Methods and results
Forty-three healthy adults at low to moderate risk of cardiovascular disease received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, inflammation, and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p = 0.005) that reached significance only in women (p = 0.045). Thrombin receptor-activating peptide (TRAP)-induced P-selectin expression was higher after supplementation in all subjects (p = 0.017). TRAP-induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p = 0.035). Plasma monocyte chemoattractant protein-1 was higher (p = 0.041) after CLA80:20.

Conclusion
No clear evidence was found for inhibition or activation of platelet function as well as inflammation by CLA80:20 in a low to moderate cardiovascular risk group.
Original languageEnglish
Pages (from-to)741-750
Number of pages10
JournalMolecular Nutrition & Food Research
Volume59
Issue number4
Early online date23 Feb 2015
DOIs
Publication statusPublished - Apr 2015

Fingerprint

Conjugated Linoleic Acids
thrombin
fibrinogen
conjugated linoleic acid
blended foods
placebos
Healthy Volunteers
thrombin receptor peptide SFLLRNP
Blood Platelets
Randomized Controlled Trials
inflammation
peptides
platelet activation
receptors
risk groups
gender
cardiovascular diseases
dietary supplements
collagen
protein synthesis

Keywords

  • cardiovascular risk
  • platelet function
  • dietary intervention
  • conjugated linoleic acid
  • fatty-acids
  • randomized controlled trial

Cite this

@article{9967d41b53354c50be2f0eaf2fbec913,
title = "Supplementation with a 9c,11t-rich conjugated linoleic acid blend shows no clear inhibitory effects on platelet function in healthy subjects at low and moderate cardiovascular risk: A randomized controlled trial",
abstract = "ScopeThe 9cis,11trans-conjugated linoleic acid (9c,11t-CLA) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated human platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t-CLA enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial.Methods and resultsForty-three healthy adults at low to moderate risk of cardiovascular disease received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, inflammation, and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p = 0.005) that reached significance only in women (p = 0.045). Thrombin receptor-activating peptide (TRAP)-induced P-selectin expression was higher after supplementation in all subjects (p = 0.017). TRAP-induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p = 0.035). Plasma monocyte chemoattractant protein-1 was higher (p = 0.041) after CLA80:20.ConclusionNo clear evidence was found for inhibition or activation of platelet function as well as inflammation by CLA80:20 in a low to moderate cardiovascular risk group.",
keywords = "cardiovascular risk, platelet function, dietary intervention, conjugated linoleic acid , fatty-acids, randomized controlled trial",
author = "Eva-Maria Bachmair and Wood, {Sharon G} and Keizer, {Hiskias G} and Horgan, {Graham W} and Isobel Ford and {de Roos}, Baukje",
note = "Isobel Ford and Baukje de Roos are joint senior authors on this publication. Acknowledgement The authors thank all the volunteers for participating in this study. The personnel of the Human Nutrition Unit at the Rowett Institute of Nutrition and Health provided excellent and expert contributions to the conduct of the trial. The Rowett Institute of Nutrition and Health and Biomathematics and Statistics Scotland receive funding from the Scottish Government Rural and Environment Science and Analytical Services (RESAS). E.M.B. received a scholarship partly funded by Stepan Specialty Products BV, The Netherlands. The supplement was provided and the trial funded by Stepan Specialty Products BV, The Netherlands. Potential conflict of interest statement: Dr. Eva-Maria Bachmair received a scholarship partly funded by Stepan Specialty Products BV during the trial. Hiskias G. Keizer is employee of Stepan Specialty Products BV. Mrs. Sharon G. Wood, Dr. Graham W. Horgan, Dr. Isobel Ford, and Dr. Baukje de Roos report no disclosures. The sponsor (represented by H.G.K.) was given the drafts for comments and suggestions but E.M.B., I.F., and B.d.R. had primary responsibility for data analysis and final content",
year = "2015",
month = "4",
doi = "10.1002/mnfr.201400495",
language = "English",
volume = "59",
pages = "741--750",
journal = "Molecular Nutrition & Food Research",
issn = "1613-4125",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Supplementation with a 9c,11t-rich conjugated linoleic acid blend shows no clear inhibitory effects on platelet function in healthy subjects at low and moderate cardiovascular risk

T2 - A randomized controlled trial

AU - Bachmair, Eva-Maria

AU - Wood, Sharon G

AU - Keizer, Hiskias G

AU - Horgan, Graham W

AU - Ford, Isobel

AU - de Roos, Baukje

N1 - Isobel Ford and Baukje de Roos are joint senior authors on this publication. Acknowledgement The authors thank all the volunteers for participating in this study. The personnel of the Human Nutrition Unit at the Rowett Institute of Nutrition and Health provided excellent and expert contributions to the conduct of the trial. The Rowett Institute of Nutrition and Health and Biomathematics and Statistics Scotland receive funding from the Scottish Government Rural and Environment Science and Analytical Services (RESAS). E.M.B. received a scholarship partly funded by Stepan Specialty Products BV, The Netherlands. The supplement was provided and the trial funded by Stepan Specialty Products BV, The Netherlands. Potential conflict of interest statement: Dr. Eva-Maria Bachmair received a scholarship partly funded by Stepan Specialty Products BV during the trial. Hiskias G. Keizer is employee of Stepan Specialty Products BV. Mrs. Sharon G. Wood, Dr. Graham W. Horgan, Dr. Isobel Ford, and Dr. Baukje de Roos report no disclosures. The sponsor (represented by H.G.K.) was given the drafts for comments and suggestions but E.M.B., I.F., and B.d.R. had primary responsibility for data analysis and final content

PY - 2015/4

Y1 - 2015/4

N2 - ScopeThe 9cis,11trans-conjugated linoleic acid (9c,11t-CLA) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated human platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t-CLA enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial.Methods and resultsForty-three healthy adults at low to moderate risk of cardiovascular disease received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, inflammation, and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p = 0.005) that reached significance only in women (p = 0.045). Thrombin receptor-activating peptide (TRAP)-induced P-selectin expression was higher after supplementation in all subjects (p = 0.017). TRAP-induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p = 0.035). Plasma monocyte chemoattractant protein-1 was higher (p = 0.041) after CLA80:20.ConclusionNo clear evidence was found for inhibition or activation of platelet function as well as inflammation by CLA80:20 in a low to moderate cardiovascular risk group.

AB - ScopeThe 9cis,11trans-conjugated linoleic acid (9c,11t-CLA) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated human platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t-CLA enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial.Methods and resultsForty-three healthy adults at low to moderate risk of cardiovascular disease received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, inflammation, and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p = 0.005) that reached significance only in women (p = 0.045). Thrombin receptor-activating peptide (TRAP)-induced P-selectin expression was higher after supplementation in all subjects (p = 0.017). TRAP-induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p = 0.035). Plasma monocyte chemoattractant protein-1 was higher (p = 0.041) after CLA80:20.ConclusionNo clear evidence was found for inhibition or activation of platelet function as well as inflammation by CLA80:20 in a low to moderate cardiovascular risk group.

KW - cardiovascular risk

KW - platelet function

KW - dietary intervention

KW - conjugated linoleic acid

KW - fatty-acids

KW - randomized controlled trial

U2 - 10.1002/mnfr.201400495

DO - 10.1002/mnfr.201400495

M3 - Article

C2 - 25641922

VL - 59

SP - 741

EP - 750

JO - Molecular Nutrition & Food Research

JF - Molecular Nutrition & Food Research

SN - 1613-4125

IS - 4

ER -